Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

20 May 2003

The impact of obesity and liver steatosis on the rate of liver fibrosis among patients with chronic hepatitis C

W. Kryczka, M. Chrapek, K. Paluch, D. Zarębska-Michaluk, A. Urbaniak

Med Sci Monit 2003; 9(2): 9-0 :: ID: 15235

Abstract

Background:To study the potential predictive role of obesity and liver steatosis (LS)on the rate of liver fibrosis (RLF)among patients with chronic hepatitis C (CHC).Material/Methods:354 consecutive,biopsy proven (assessed according to Ishak ’s criteria)patients (mean age at biopsy: 42 ±14 years;F/M:178/176)with untreated CHC and known probable duration of HCV infection were seen.Subject with other forms of liver disease as well as heavy drinkers were excluded from analysis.The RLF was defined as the ratio between fibrosis stage (scored 0 –6 units with 6 representing cirrhosis)and the duration of infection (in years). Based on published data,a patient with RLF>/=0,3 (cirrhosis up to 20 years after HCV infection)was considered as rapid progressor. The obesity was defined as body mass index >30 kg/m 2 .In our analysis,the LS was graded as 0,1,2 respectively to less than 1% (or absence),1 –10%and more than 10%hepatocytes involved. Results: Overall, 15% (54/354)patients were rapid progressors. 13%(46/354)patients were obese and the grade 0,1 and 2 of LS was observed in 58% (201/354), 34%(121/354) and 9% (32/354)of patients, respectively.The rapid progressors were significantly more frequently noted among obese than among non-obese patients (30%vs.13%;p=0,004)as well as among patients with increasing LS (12%,17%and 28%rapid progressors,respectively among patients with grade 0,1 and 2 of LS; p=0.04).In logistic regression analysis,after adjusting for age at biopsy and sex,only obesity (adjusted OR=2,2; 95%CI [1.1 –4.7 ];p=0.03)and not LS (p=0.21)was an independent predictor of rapid progression to cirrhosis.Conclusions:Our study confirmed recently published findings indicating that obesity maybe considered as a predictor of rapid disease progression in CHC patients.It suggests that weight reduction may play a significant role in hepatitis C management and constitute an alternative,especially among non-responders or patients with contraindications to interferon therapy

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750